Antinephrotoxic and antihyperlipidaemic activities of Cucurbita maxima leaf supplemented diets in stz-induced diabetic rats

Background:Cucurbita maxima plant materials are frequently used to manage a number of disorders,according to previous studies.Objective:The goal of the present report was to look into further possible effects of this plant on kidney disorder in rats brought on by diabetes as well as the related abnormalities in lipid metabolism.Methods:To assess the ameliorative effect of the plant,streptozotocin(STZ)(45 mg/kg/day)was given as a single dosage to cause type 1 diabetes.After then,diabetic rats received supplemented diets of Cucurbita maxima for four weeks at 5%,10%,15%and 20%ad libidium.However,in another experiment to evaluate the preventive capacity of Cucurbita maxima,the STZ-induction came at the end of four weeks supplementation.Blood and kidney tissues were obtained at the end of the treatments and investigated.Consequently,the analysis of kidney function and lipid profile was made using serum obtained from the blood sample.Histological change in kidney was also observed using haematoxylin and eosin stain Results:Our findings demonstrated that Cucurbita maxima drastically(P<0.05)decreased the elevated kidney indicators such as urea and creatinine in the blood,and restored the electrolytes and lipid profiles anomalies as compared to the normal control.However,the alteration of biochemical parameters in the STZ-induced diabetic control remained unchanged throughout as compared to the normal control.The above mentioned biochemical changes that took place in kidney tissues were further corroborated by histological alterations.Conclusion:The results suggest that Cucurbita maxima leaves supplemented diets reversed STZ-induced renal disorder and abnormal lipid metabolism,and that these effects may be mediated by interacting with multiple receptors to raise the levels of antioxidant enzymes in the system.

Anti-hyperlipidaemic assay and LC-MS/MS determination of piperinic ester in rat

In the present study, we aimed to establish high-fat diet model for evaluating anti-hyperlipidaemic activity of GBA and to establish the HPLC-MS method for measuring the pharmacokinetics of GBA in rat blood plasma and liver after oral administration. Rats were orally administrated with GBA at the dose of 50mg/kg body weight. GBA concentrations in blood plasma and liver were detected by HPLC from 0.5–10 h post administrations. The pharmacokinetic parameters were analyzed by the DAS1.0Software. The concentration-time curves of the plasma GBA and liver GBA wereconformed to two-compartment model. GBA was rapidly absorbed in the gastrointestinal tract and could be detected in plasma and liver 0.5 h after oral administration.